PRECIGEN, INC.
Precigen is a commercial-stage biopharmaceutical company developing precision medicines for immuno-oncology, autoimmune disorders and infectious diseases. Its platforms include AdenoVerse immunotherapy and UltraCAR-T, supported by technologies for designing gene programs, delivering them through viral and non-viral methods, and controlling gene expression. Precigen’s commercial product, Papzimeos, is an FDA-approved immunotherapy for adults with recurrent respiratory papillomatosis. Its clinical programs include PRGN-2009, an investigational immunotherapy for HPV-associated cancers, and PRGN-3006, an investigational CAR-T therapy for relapsed or refractory acute myeloid leukemia. Precigen makes money by selling Papzimeos, which it launched in the United States. It also develops product candidates for potential clinical use and commercialization, independently or with collaborators. The company has internal manufacturing capabilities for AdenoVerse-based therapeutics and operates a manufacturing facility in Germantown, Maryland.
No SEC Form 4 filings for $PGEN in the last 30 days.
See all $PGEN insider activity →Precigen (PGEN) reported Q3 earnings, highlighting growth indicators and $51M in cash. The company discussed competition, clinical data for PAPZIMEOS, and development plans. No Q4 revenue guidance was provided. Precigen expects to collect $96.5M in trade receivables and has access to additional borrowing capacity.
Precigen reported Q3 GAAP EPS of $0.08, meeting estimates, and revenue of $74.1M, exceeding expectations by $2.54M. Revenue grew 2437.7% year-over-year, according to the company. Shares fell 3.5% after hours.
Precigen (PGEN) shares dropped 20% premarket after Inovio's (INO) FDA-approved rival treatment, Voceryq, challenged Papzimeos. PGEN reported $53.1M Q2 revenue. Retail investors remain optimistic about a potential buyout. Voceryq expects shipments in 60 days, with full deployment in early 2027. Clinical trials showed higher surgery-free rates for Papzimeos (51%) vs. Voceryq (27%).
Over the past 7 days, AlphAI's AI scored 9 news stories mentioning PGEN (PRECIGEN, INC.). Coverage has skewed bearish: 2 bullish, 3 neutral, and 4 bearish.
Recent PGEN coverage spans market movers, financial news and earnings.
Neutral impact as the call provided no new quantitative guidance.
Earnings beat on revenue but in-line EPS and modest after‑hours decline suggest limited upside.
PGEN likely faces selling pressure as the competitor's approval raises doubts about its product's market share.
The announcement sets a date for the upcoming earnings release, creating a short‑term focus on the stock.
FDA platform designation plus a successful first-drug launch are framed as de-risking the pipeline and supporting upside expectations ahead of upcoming trial readouts.
AlphAI scores every news story that mentions PGEN with an AI model for sentiment and relevance, and aggregates insider trades from PRECIGEN, INC.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Precigen (PGEN) reported Q3 earnings, highlighting growth indicators and $51M in cash. The company discussed competition, clinical data for PAPZIMEOS, and development plans. No Q4 revenue guidance was provided. Precigen expects to collect $96.5M in trade receivables and has access to additional borrowing capacity.
Precigen reported Q3 GAAP EPS of $0.08, meeting estimates, and revenue of $74.1M, exceeding expectations by $2.54M. Revenue grew 2437.7% year-over-year, according to the company. Shares fell 3.5% after hours.
Precigen (PGEN) shares dropped 20% premarket after Inovio's (INO) FDA-approved rival treatment, Voceryq, challenged Papzimeos. PGEN reported $53.1M Q2 revenue. Retail investors remain optimistic about a potential buyout. Voceryq expects shipments in 60 days, with full deployment in early 2027. Clinical trials showed higher surgery-free rates for Papzimeos (51%) vs. Voceryq (27%).
Precigen, Inc. (PGEN) will release Q3 2026 financial results and business updates on November 4, 2026, hosting a conference call at 4:30 PM ET. The company focuses on precision medicines for immuno-oncology, autoimmune disorders, and infectious diseases, with a pipeline including PAPZIMEOS for recurrent respiratory papillomatosis.
Patient Capital Management's Q3 2026 investor letter highlights Precigen (PGEN) as a top holding. The biopharmaceutical company's stock has gained ~86.84% YTD, driven by the successful launch of its drug Papzimeous. The company's market cap is $2.8 billion, and it recently received FDA platform designation for its Adenoverse technology.
On September 30, 2026, biotech stocks PGEN, EXEL, TWST, HNGE, and PBYI hit 52-week highs. PGEN rose 6% to $9.98, EXEL reached $61.14, TWST climbed 3% to $197.19, HNGE hit $98.41, and PBYI touched $10.10. Key catalysts included clinical trial results, FDA designations, and revenue growth.
Precigen (PGEN) received FDA Platform Technology Designation for AdenoVerse, the technology behind PAPZIMEOS. The designation may reduce development costs for future drugs, including PRGN-2009, an investigational cancer treatment. Management expects benefits but has not quantified cost savings or timelines. The FDA's draft guidance outlines potential benefits, but Precigen must provide supporting evidence for reuse of prior data. Hedge fund sentiment showed a slight decrease in holdings.
Mizuho initiated coverage on Tower Semiconductor (TSEM) with an Outperform rating and $300 price target. Other initiations include Precigen (PGEN) with a Buy rating and $12 target, Seaport Therapeutics (SPTX) with a Strong Buy rating and $46 target, PDF Solutions (PDFS) with a Buy rating and $60 target, and CF Industries (CF) with an Outperform rating and $162 target.
Precigen, Inc. (PGEN) announced that the FDA granted platform technology designation to its AdenoVerse® immunotherapeutic platform, used in its commercial product PAPZIMEOS®. This designation may accelerate the development of future therapies by leveraging existing data and reducing duplicative work. The company's CEO highlighted the potential benefits for its clinical portfolio, including PRGN-2009 for HPV-associated cancers.
KINDLER JEFFREY B sold 185,000 shares of PRECIGEN, INC. (PGEN) at $7.44 ($1.38M total) on 2026-08-26.
